A landmark week across oncology, with pivotal data in lung, prostate, bladder, and haematological cancers reshaping treatment paradigms in both early and advanced disease. Gene editing, RNA therapeutics, and AI drug discovery attracted major capital commitments. Kidney disease emerged as a strategic battleground. A persistent US drug pricing gap versus other high-income countries remained unresolved.

This week's edition of Pharma Phriday (April 10, 2026) spans late-stage clinical results in thyroid eye disease, achondroplasia, small cell lung cancer, hidradenitis suppurativa, macular degeneration, and inflammatory respiratory conditions; regulatory approvals and submissions in rare and chronic disease; and a flurry of M&A and partnership activity spanning oncology, rare disease, and drug delivery innovation.

According to an annual PwC study released in December, the amount of M&A activity in the pharmaceutical and life sciences sectors in 2024...